Monthly Archives - December 2017

Boehringer Ingelheim highlights progress of immuno-oncology collaborations

In the last year, the firm has worked with the University of California at Los Angeles to develop a promising vaccine platform that can deliver a self-replicating RNA vaccine cargo to cancerous cells, helping the immune system to eliminate the cancer.
It has also partnered with Siamab Therapeutics to identify anticancer therapeutics that target tumour-associated carbohydrate antigens, while another collaboration with AbeXXa Biologics has been formed to identify new selective molecular targets for cancer from the thousands of proteins found […]

TetraGenetics Partners with LifeArc to Humanize New Drugs and Perform IND-Enabling Studies

TetraGenetics, a biopharmaceutical company developing novel therapeutics for autoimmune diseases and pain, today announced a partnership with LifeArc®, the UK-based medical research charity. The collaboration brings together the drug discovery skills of TetraGenetics with the antibody humanization and development capabilities of LifeArc. Under the agreement LifeArc will humanize up to five new drug leads discovered by TetraGenetics and may support pre-IND (Investigational New Drug) studies for selected programs. TetraGenetics will manage the regulatory applications and the subsequent clinical trials […]

When the Investment Banker Comes Calling

Boston Harbor Angel members, Ziad Moukheiber and David Powsner, are the hosts of Failure – the Podcast, a podcast about about business failures, focusing on startups and emerging companies.
In episode four, Moukheiber and Powsner chat with Jack Langworthy, of Covington Associates, as he looks at startups from an investment banker’s perspective. Tune in >>

TetraGenetics and ModiQuest Collaborating for the Discovery of Therapeutic Antibodies Against KCa3.1

TetraGenetics, a biopharmaceutical company developing novel therapeutics for autoimmune diseases, today announced a collaboration with ModiQuest Research, a Dutch biotechnology company with a suite of technologies for the discovery and optimization of monoclonal antibodies including those directed against difficult target antigens with low immunogenicity. Read more >>

Myomo, Inc. Announces Full Exercise of Underwriter’s Over-Allotment Option in Follow-On Public Offering

Myomo, Inc. (NYSE American: MYO), a commercial stage medical robotics company, today announced that Roth Capital Partners, the underwriter of Myomo’s follow-on offering, exercised in full its option to purchase 626,250 shares of common stock and accompanying warrants to purchase 626,250 shares of common stock, at a combined price to the public of $2.40 per share of common stock and accompanying warrant, for gross proceeds of approximately $1.5 million. Read more >>